Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine (Medis)

November 3, 2020 updated by: University Hospital, Grenoble

Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine

The purpose of this study is to determine whether TDCS is an effective prophylactic therapy of chronic migraine.

Study Overview

Detailed Description

Consenting patients will report on a book, all of their migraine attack for 1 month. Then they will be randomized to the active tDCS group or sham tDCS group. Patients will have one session of tDCS per day during the first week, then one session per week for a month and finally a session every 15 days for 1 month. After tDCS sessions, patients will be followed for 3 months. Throughout their participation in the study, patients will complete their migraine record (1month of base line before tDCS, 2 months during tDCS, 3 months after tDCS).

Patients will have 5 evaluation examinations:

  • The first, one before tDCS,
  • The second, 1 month after the beginning of tDCS
  • The third, immediately after the end of tDCS
  • The fourth, 1 month after the end of tDCS
  • And the last one, 3 months after the end of tDCS.

The physician responsible for conducting tDCS sessions will make the randomization via a website.

The physician in charge of the evaluation examinations will don't know the allocated treatment.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Isere
      • Grenoble, Isere, France, 38043
        • Grenoble University Hospital
      • Voiron, Isere, France, 38500
        • Hospital of Voiron

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of chronic migraine for more than 1 year
  • Stable treatment since 1 month
  • Frequency of migraine crisis is above 8 per month during last month
  • chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted
  • Patient agreeing not to try other migraine prophylactic treatment, throughout the study
  • Patient's written consent

Exclusion Criteria:

  • History of drug addiction, epilepsy, or severe head trauma with bone break
  • History of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study
  • Presence of intracranial ferromagnetic material or an implanted stimulator
  • Introduction of a new treatment for less than a month
  • Pregnant women, parturient women, breast-feeding mother. Lack of effective contraception
  • Person not understanding the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: active tDCS

The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.

Stimulation parameters:

  • 2 mA intensity
  • Continuous stimulation for 20 min with rise times and fall times of 10 seconds each
Placebo Comparator: simulated tDCS

The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.

Stimulation parameters:

  • The intensity of the stimulation current is 2 mA
  • The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparison of the evolution of seizure frequency between the two groups
Time Frame: Evolution of seizure frequency since base line to 3 months after the end of tDCS
Evolution of seizure frequency since base line to 3 months after the end of tDCS

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the evolution of seizure severity between the two groups
Time Frame: Evolution of seizure severity since base line to 3 months after the end of tDCS
Headache Impact Test 6 (HIT-6) questionnaire
Evolution of seizure severity since base line to 3 months after the end of tDCS
Comparison of the evolution of crisis treatment use between the two groups
Time Frame: Evolution of crisis treatment use since base line until 3 months after the end of tDCS
Frequency of taking crisis treatment. After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.
Evolution of crisis treatment use since base line until 3 months after the end of tDCS
Comparison of the evolution of the disease impact between the two groups
Time Frame: Evolution of the disease impact since base line to 3 months after the end of tDCS
Migraine Disability Assessment Scale (MIDAS) scale
Evolution of the disease impact since base line to 3 months after the end of tDCS
Comparison of the evolution of the patient satisfaction between the two groups
Time Frame: Evolution of the patient satisfaction since base line to 3 months after the end of tDCS
Clinical Global Impression (CGI) scale
Evolution of the patient satisfaction since base line to 3 months after the end of tDCS
Comparison of the evolution of the quality of life between the two groups
Time Frame: Evolution of the quality of life since base line until 3 months after the end of tDCS
Short Form 12 (SF-12) quality of life questionnaire
Evolution of the quality of life since base line until 3 months after the end of tDCS
Comparison of the evolution of anxiety and depression levels between the two groups
Time Frame: Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS
Hospital Anxiety and Depression scale (HAD) questionnaire
Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: HODAJ Hasan, MD, University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2014

Primary Completion (Actual)

December 18, 2019

Study Completion (Actual)

June 23, 2020

Study Registration Dates

First Submitted

April 15, 2014

First Submitted That Met QC Criteria

April 17, 2014

First Posted (Estimate)

April 22, 2014

Study Record Updates

Last Update Posted (Actual)

November 4, 2020

Last Update Submitted That Met QC Criteria

November 3, 2020

Last Verified

November 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Migraine as Defined by Criteria of International Headache Society (IHS)

Clinical Trials on Transcranial direct current stimulation of the motor cortex

3
Subscribe